Xenon Pharmaceuticals
XENE
204 hedge funds and large institutions have $3.32B invested in Xenon Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 85 increasing their positions, 52 reducing their positions, and 19 closing their positions.
142% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 19
63% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 52
58% more capital invested
Capital invested by funds: $2.1B → $3.32B (+$1.22B)
56% more funds holding in top 10
Funds holding in top 10: 9 → 14 (+5)
13% more funds holding
Funds holding: 180 → 204 (+24)
1.89% more ownership
Funds ownership: 95.63% → 97.52% (+1.9%)
4% less call options, than puts
Call options by funds: $39M | Put options by funds: $40.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$86M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.6M |
| 3 |
BlackRock
New York
|
+$38M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$36.9M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$31.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$33.1M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$27.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$22.1M |
| 4 |
SC
Samlyn Capital
New York
|
-$18.7M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$16.1M |
XENE Hedge Fund Activity: Q4 2023 in Review
204 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2023, worth a combined $3.32B — up 58% from $2.1B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new XENE positions and 19 closed out — a net gain of 27 holders — while 85 added to existing stakes and 52 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $86M. The largest seller was BVF Inc, cutting an estimated $33.1M.
- 204 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2023, up from 180 in Q3 2023.
- Funds reported $3.32B of Xenon Pharmaceuticals stock for Q4 2023, up 58% quarter-over-quarter.
- 46 funds opened new Xenon Pharmaceuticals positions in Q4 2023 and 19 closed out, a net change of +27 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2023 was Wellington Management Group, an estimated $86M added.
- The largest Xenon Pharmaceuticals seller in Q4 2023 was BVF Inc, an estimated $33.1M sold.
Based on aggregated 13F filings for Q4 2023.